Conseil d'examen du prix des médicaments brevetés - Patented Medicine Prices Review Board Canada Wordmark
 
 Français  Contact Us  Help  Search  Canada Site
Home About the
 PMPRB
Order Forms
Feedback
Sitemap
Archives
 Other Sites

Home > REMICADE-Schedule of Events Printer Friendly

Schedule of Events
Revised- 2003-02-14

IN THE MATTER OF the Patent Act R.S.C. 1985, c. P-4,
as amended

AND IN THE MATTER OF Schering Canada Inc.
(the “Respondent”) and the medicine “Remicade”

Event / Filing

Date / Deadline

Notice of Hearing - Issuance

December 16, 2002

Service of Respondent

December 17, 2002

Confirmation of Service

December 17, 2002

Service of Minister of Industry Canada

December 17, 2002

Service of provincial/territorial ministers of health

December 17, 2002

Issuance of press release

December 17, 2002

Publication of Notice of Hearing – Canada Gazette, Part I

December 21, 2002

Respondent Filing

January 27, 2003

Filing of intentions
- Minister of Industry Canada
- Provincial/territorial ministers of health

January 20, 2003
January 13, 2003

Application for leave to intervene

January 7, 2003

Response to application for leave to intervene

January 30, 2003

Filing of Notice of Motions – preliminary matters

January 31, 2003

Filing of Response – preliminary matters

February 6, 2003

Pre-Hearing memoranda

February 6, 2003

Pre-Hearing conference

February 11, 2003

Filing of Proposed Order by Board Staff

February 14, 2003

Filing of list of documents by Board Staff

February 21, 2003

Filing by Board Staff of Reply to the Response

February 21, 2003

Filing of list of documents by Respondent

March 7, 2003

Pre-Hearing conference 1

March 21, 2003

Filing of Expert Reports and Witness Statements by Board Staff 2

April 7, 2003

Filing of Expert Reports and Witness Statements by Respondent

April 11, 2003

Filing of Reply Expert Reports and Statements by Board Staff 3

April 17, 2003

Hearing - to commence on

April 22


  1. Video conference – to be confirmed
  2. The Board will allow parties to lead their expert witness to the extent necessary to establish the contents of their reports.
  3. Examination of materials may take place at subsequent sessions.



Last Updated: 2006-04-17 Arrow Important Notices